...
首页> 外文期刊>Saudi Journal of Biological Sciences >Poloxamer-chitosan-based Naringenin nanoformulation used in brain targeting for the treatment of cerebral ischemia
【24h】

Poloxamer-chitosan-based Naringenin nanoformulation used in brain targeting for the treatment of cerebral ischemia

机译:基于泊洛沙姆 - 壳聚糖的鼻嘌呤纳米蛋白纳米型用于脑靶向脑缺血的靶向

获取原文

摘要

Objective Here, the aim is to improve the bioavailability of Naringenin (NRG) in brain and to establish the highest remedial benefit from a novel anti-ischemic medicine i.e. NRG. Methods A novel Naringenin-loaded-nanoemulsion (NE)-( in situ )-gel (i.e. thermoresponsive), was formulated with the help of Poloxamer-407 (20.0% w/v). Chitosan (CS, 0.50% w/v) was used to introduce the mucoadhesive property of NE-( in situ )-gel and finally called as NRG-NE-gel?+?0.50%CS. A novel UHPLC-ESI-Q-TOF-MS/MS-method was optimized and used for NRG-NE-gel?+?0.50%CS to quantify the Pharmacokinetic-(PK)-parameters in plasma as well as brain and to evaluate the cerebral ischemic parameters after MCAO i.e. locomotor activity, grip strength, antioxidant activity, and quantity the infarction volume in neurons with the safety/toxicity of NRG-NE-gel?+?0.50%CS after i.n. administration in the rats. Results The mucoadhesive potency and gelling temperature of NRG-NE-gel?+?0.50%CS were observed 6245.38 dynes/cm 2 and 28.3?±?1.0?°C, respectively. Poloxamer-407 based free micelles size was observed 98.31?±?1.17?nm with PDI (0.386?±?0.021). The pH and viscosity of NRG-NE-gel?+?0.50%CS were found to be 6.0?±?0.20 and 2447?±?24cp (at 35.0?±?1.0?°C temperature), respectively. An elution time and m / z NRG were observed 1.78?min and 270.97/150.96 with 1.22?min and m / z of 301.01/150.98 for Quercetin (IS) respectively. Inter and intra %precision and %accuracy was validated 1.01–3.37% and 95.10–99.30% with a linear dynamic range (1.00 to 2000.00?ng/ml). AUC 0-24 of plasma & brain were observed 995.60?±?24.59 and 5600.99?±?144.92 (ng min/ml g) in the rats after the intranasal (i.n.) administration of NRG-NE-gel?+?0.50%CS. No toxicological response were not found in terms of mortalities, any-change morphologically i.e. in the microstructure of brain as well as nasal mucosa tissues, and also not found any visual signs in terms of inflammatory or necrosis. Conclusion Intranasally administered NRG-NE-gel?+?0.50%CS enhanced the bioavailability of Naringenin in the brain. In the cerebral ischemic rats, significantly improved the neurobehavioral activity (locomotor & grip strength) followed by antioxidant activity as well as infarction volume. Finally, the toxicity studies carried out and established the safe nature of optimized-NRG-NE-gel?+?0.50%CS.
机译:目的在这里,目的是提高大脑(NRG)在大脑中的生物利用度,并从新型抗缺血药物中建立最高的补救福利.. NRG。方法在泊洛沙姆-407(20.0%w / v)的帮助下配制新型鼻腔加载纳米乳液(NARINGEN-LOAD纳米乳液(NE) - (原位) - (I.IE.ITHU) - (即热响应性)。壳聚糖(CS,0.50%w / v)用于引入Ne-(原位)-gel的粘膜粘附性,最后称为NRG-NE-凝胶?+ 0.50%Cs。优化了一种新型的UHPLC-ESI-Q-TOF-MS / MS方法并用于NRG-NE-凝胶α+ +?0.50%CS,以量化血浆和大脑中的药代动力学 - (PK)分子,并评估MCAO后的脑缺血参数,即运动活性,握持强度,抗氧化活性,以及​​神经元的梗死体积,具有NRG-NE-凝胶的安全性/毒性?+α+?0.50%CS在大鼠施用。结果分别观察到NRG-NE-凝胶的粘膜粘附性效力和胶凝温度分别观察到0.50%CS的粘膜效应和胶凝温度。泊洛沙姆-407基于的游离胶束尺寸被观察到98.31≤1.17Ω·NM,PDI(0.386?±0.021)。发现NRG-NE-凝胶的pH和粘度分别为0.50%CS为6.0°±0.20和2447?±24cp(在35.0?±1.0℃温度)。观察洗脱时间和M / Z NRG 1.78?min,270.97 / 150.96分别为1.22Ω·min,m / z 301.01 / 150.98分别用于槲皮素(是)。 Inter和Intra%精度和%精度验证了1.01-3.37%和95.10-99.30%,线性动态范围(1.00至2000.00?ng / ml)。在NRG-NE-凝胶施用NRG-NE-凝胶施用后的大鼠中,观察到血浆和大脑的AUC 0-24±24.59和5600.99?±144.92(Ng min / ml g)α+ 0.50%Cs 。在凡人的情况下没有发现毒理学反应,任何形态学上,即在大脑和鼻粘膜组织的微观结构中,也没有发现炎症或坏死方面的任何视觉迹象。结论鼻内给药NRG-NE-凝胶?+ 0.50%CS增强了大脑中柚皮蛋白的生物利用度。在脑缺血大鼠中,显着改善了神经兽性活性(运动夹具强度),然后是抗氧化活性以及梗死体积。最后,进行了毒性研究,并建立了优化的NRG-NE-凝胶的安全性?+?0.50%Cs。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号